MedTrace Logo

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00333216 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-11-28

No results posted yet for this study

Summary

The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.

Conditions

Interventions

DRUG

Anecortave Acetate Sterile Suspension, 30 mg/mL

Posterior juxtascleral administration of suspension

DRUG

Anecortave Acetate Sterile Suspension, 60 mg/ML

Posterior juxtascleral administration of suspension

OTHER

Anecortave Acetate Vehicle

Sham posterior juxtascleral administration of suspension

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Terry Wiernas, PhD · Study Director

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333216 on ClinicalTrials.gov